Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06827236 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
A Phase 1 study of Metastatic Breast Cancer and Locally Advanced Breast Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 380
- Enrollment target
- 20
- Study locations
NCT06827236 is a Phase 1 study of Metastatic Breast Cancer and Locally Advanced Breast Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 380 participants, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (88% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06827236, a Phase 1 study of Metastatic Breast Cancer and Locally Advanced Breast Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 380 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).
Conditions Studied
Interventions
- DRUG BNT327
- DRUG BNT323
Study Locations (20)
Other
- Sunnybrook Health Sciences Centre - Toronto
- The First Affiliated Hospital of Bengbu Medical College - Bengbu
- Jilin Cancer Hospital - Changchun
- Sichuan Cancer Hospital - Chengdu
- Sichuan Provincial People's Hospital - Chengdu
- Huizhou First Hospital - Huizhou
- Guangxi Medical University Affiliated Tumor Hospital - Nanning
- Fudan University Shanghai Cancer - Shanghai
- Clinique Victor Hugo - Centre Jean Bernard - Le Mans
- Institut Claudius Regaud - Toulouse
- LLC Arensia Exploratory Medicine - Tbilisi
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
- Washington University School of Medicine - St Louis
California
- Beverly Hills Cancer Center - Beverly Hills
Florida
- Hematology - Oncology Associates of the Treasure Coast - Port Saint Lucie
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Michigan
- START Midwest, LLC - Grand Rapids
New Jersey
- Summit Medical Group - Florham Park
New York
- Memorial Sloan Kettering Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06827236
The ClinicalTrials.gov registry entry for NCT06827236 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (88% higher). The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which BNT327 is the first listed.
NCT06827236 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT06827236 about?
NCT06827236 is a clinical study titled "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer". This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth f...
What is the current status of trial NCT06827236?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2025-04-23. Estimated completion is 2029-05.
What conditions does trial NCT06827236 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma.
What interventions are being tested in trial NCT06827236?
The interventions under investigation include: BNT327 (DRUG), BNT323 (DRUG).
Who is sponsoring clinical trial NCT06827236?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06827236 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.